Disease · MONDO_0005586

head and neck neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. head and neck neoplasm. Diseases, record MONDO_0005586. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005586

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: head and neck neoplasm; Open Targets
Open Targets ID: MONDO_0005586; Open Targets
Other names: craniocervical region neoplasm, craniocervical region neoplasm (disease), craniocervical region tumor, craniocervical region tumour, head and neck neoplasia, head and neck neoplasm (excluding central nervous system), head and neck tumor, head and neck tumour, neoplasm of craniocervical region, neoplasm of head and neck, neoplasm of the head and neck, tumor of craniocervical region, tumor of head and neck, tumor of the head and neck, tumour of craniocervical region, tumour of head and neck, tumour of the head and neck; Open Targets
NCI Thesaurus: C3077; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 24 drugs, from EMA Human Drugs; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOCETAXEL	CHEMBL3545252	Small molecule	Approval	EMA Human Drugs	9	0	0	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Approval	EMA Human Drugs	1	0	0	Drugs and targets
TEMOPORFIN	CHEMBL500576	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
SERPLULIMAB	CHEMBL4594550	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MOLGRAMOSTIM	CHEMBL2109134	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
PIMURUTAMAB	CHEMBL4594549	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
REGRAMOSTIM	CHEMBL2107881	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
SARGRAMOSTIM	CHEMBL1201670	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
AMINOLEVULINIC ACID HYDROCHLORIDE	CHEMBL1200582	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets54

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 54

See all 54 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00666926	Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms	Phase 1	99	2012-06-14	Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm	PF-00562271	Its record names the disease	ClinicalTrials.gov
NCT04297995	Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors	Phase 2	131		Head and Neck Squamous Cell Carcinoma	FLUOROURACIL, PIMURUTAMAB, SERPLULIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00978081	Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors	Phase 1	35		Head and Neck Cancer, Precancerous Condition	AMINOLEVULINIC ACID HYDROCHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT06716619	A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors	Phase 1	32		Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection	SERPLULIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04866498	Pharmacotherapy Personalization of Cancer Patients		22		Head and Neck Neoplasms, Oncologic Patients	DEXMEDETOMIDINE, ETOMIDATE, FENTANYL, MIDAZOLAM, OXYCODONE, PROPOFOL, ROCURONIUM, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT05200650	A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor	Phase 1	20		Head and Neck Cancer	CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT05490381	Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes	Phase 1	0		Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck	ETHIODIZED OIL, POLYVINYL ALCOHOL	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
40932107	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005586

GET https://conductscience.org/api/diseases/v1/MONDO_0005586/drugs?page=2

API reference For AI assistants